Significant Association Among the Epigenetic Alterations in EGFR and ALK Genes and Non–Small Cell Lung Cancer: A Prospective Emerging Molecular Biomarker
Annals of Human Genetics · 2025
DOI: 10.1111/ahg.12597 ↗Kurz gefasst
Fachartikel in der Zeitschrift Annals of Human Genetics, 2025. Verfasst von Fatemeh Sadri und 2 weiteren Autor:innen. Beteiligte Einrichtung: Molecular Medicine Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, ErbB Receptors, Epigenesis, Genetic. Die Arbeit nennt 47 Literaturangaben. Gefördert von: Vice-Chancellor for Research, the Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
Abstract (Originalsprache)
Background
Non–small cell lung cancer (NSCLC) is increasingly recognized as a heterogeneous set of diseases at the molecular level, and these differences likely could drive therapeutic decision‐making. The anaplastic lymphoma kinase ( ALK ) and epidermal growth factor receptor (EGFR) genes are two key oncogenes of tyrosine kinase that their expression is increased in lung cancer and activates their downstream signaling cascade. These two genes have been identified as therapeutic targets, and targeted therapies for these genes by tyrosine kinase inhibitors have been approved by the FDA.
Objective
We aimed to elucidate the epigenetic alterations in ALK and EGFR genes in NSCLC patients.
Methods
Fifty tissue samples of the paired NSCLC samples and adjacent normal tissues were evaluated by methylation‐specific polymerase chain reaction (MS‐PCR). Subsequently, the methylation status of the EGFR and ALK genes promoter was examined by bioinformatics tools such as UCSC, GTEx portal, and iMETHYL servers.
Results
There was a significant difference in the methylation pattern of EGFR (Region II) ( p = 0.02) between the case and control groups and also that patients who were methylated in this region of the EGFR promoter had a higher stage than non‐methylated patients, which was statistically significant ( p = 0.03).
Conclusion
We analyzed methylation changes of EGFR and ALK genes in patients suffering from NSCLC. Alteration of EGFR gene methylation pattern could play an important role in the pathogenesis of NSCLC. To delineate the potential role of ALK somatic alterations, further investigations are warranted.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Molecular Medicine Research Center, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.
- Department of Medical Biotechnology and Molecular Medicine, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
Förderung
- Vice-Chancellor for Research, the Hormozgan University of Medical Sciences, Bandar Abbas, Iran
Zitieren
APA
Sadri, F., Alipour, M., & Nejatizadeh, A. (2025). Significant Association Among the Epigenetic Alterations in EGFR and ALK Genes and Non–Small Cell Lung Cancer: A Prospective Emerging Molecular Biomarker. Annals of Human Genetics. https://doi.org/10.1111/ahg.12597
Vancouver
Sadri F, Alipour M, Nejatizadeh A. Significant Association Among the Epigenetic Alterations in EGFR and ALK Genes and Non–Small Cell Lung Cancer: A Prospective Emerging Molecular Biomarker. Annals of Human Genetics. 2025. doi:10.1111/ahg.12597
BibTeX
@article{Sadri2025,
author = {Sadri, Fatemeh and Alipour, Mohsen and Nejatizadeh, Azim},
title = {Significant Association Among the Epigenetic Alterations in EGFR and ALK Genes and Non–Small Cell Lung Cancer: A Prospective Emerging Molecular Biomarker},
journal = {Annals of Human Genetics},
year = {2025},
doi = {10.1111/ahg.12597}
}
EUVIMED